SANN.SW Santhera (SIX) closed CHF13.34 on 12 Feb 2026: catalyst supports upside

We saw SANN.SW stock close at CHF 13.34 on 12 Feb 2026 on the SIX exchange, marking a strong session for Santhera Pharmaceuticals (Switzerland). Volume reached 48,691 shares and price momentum followed recent pipeline updates that traders flagged as the day’s catalyst. We note the stock’s YTD gain of 22.73% and position this move against mixed fundamentals and active clinical-readout risk. As an AI-powered market analysis platform, Meyka highlights where the price action ties to fundamentals and what investors should watch next.

SANN.SW stock price action and session details

Santhera (SANN.SW) closed CHF 13.34 on the SIX on 12 Feb 2026 with intraday volume 48,691. The session showed a clear bid after newsflow, lifting the stock above its 50-day average of CHF 12.75. Traders should note the day range was CHF 13.10–13.46 which suggests higher intraday interest.

SANN.SW stock drivers: pipeline and news flow

The primary driver remains clinical progress for vamorolone and other pipeline assets, which investors cite as the catalyst for today’s move. Santhera’s website lists ongoing programs and licensing arrangements that shape revenue optionality and sentiment Santhera.

SANN.SW stock fundamentals and valuation

Santhera shows EPS -5.38 and PE -2.77, reflecting a clinical-stage biotech profile with negative earnings. Market cap is CHF 207,712,064.00 and shares outstanding are 13,940,407.00. Price-to-sales sits near 4.24, while cash per share is CHF 1.44, highlighting funding sensitivity and valuation gaps versus large healthcare peers.

SANN.SW stock technicals and Meyka grade

Technicals show an RSI of 68.08 and ADX 41.93, pointing to strong trend momentum but near overbought conditions. Meyka AI rates SANN.SW with a score out of 100: 70.41 (Grade B+, Suggestion: BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors.

SANN.SW stock forecast and price targets

Meyka AI’s forecast model projects a 12‑month target of CHF 16.71, implying an upside of 25.29% from the current CHF 13.34 price. The model also shows a 3‑year projection of CHF 21.06 for bullish scenarios. Forecasts are model-based projections and not guarantees.

SANN.SW stock risks and sector context

Key risks include clinical trial setbacks, licensing outcomes, and funding needs; current debt metrics and negative operating cash flow underscore capital risk. In the Swiss Healthcare sector, larger peers show stronger margins and scale, so Santhera’s small market cap and binary trial outcomes raise volatility and liquidity risk.

Final Thoughts

SANN.SW stock closed CHF 13.34 at the SIX market close on 12 Feb 2026, supported by pipeline-related sentiment and above‑average intraday volume of 48,691. Our technical read shows strong trend momentum but nearing overbought territory, while fundamentals still reflect clinical-stage risk with EPS -5.38 and limited cash per share. Meyka AI’s forecast model projects a 12‑month target of CHF 16.71, an implied upside of 25.29% versus today’s price; the 3‑year view reaches CHF 21.06 under constructive clinical outcomes. We highlight three practical takeaways: manage position size around binary clinical events, watch quarterly liquidity metrics and license updates, and use the CHF 16.71 model target as a reference—adjusting for risk tolerance. For direct company information visit Santhera’s site and our SANN page for live updates Meyka stock page. Forecasts and grades are model outputs and not investment guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.